Inaccurate data in my meta-analysis of prolonged macrolides for patients with non-cystic fibrosis bronchiectasis in adult
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): Guang-Ying Zhuo , Qing He (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Inaccurate data in meta-analysis of macrolides by Guang-Ying et al
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): D.J. Serisier (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials
Conclusions Macrolide maintenance therapy was effective in reducing pulmonary exacerbations, and improving lung function in adults with NCFB. However, it did not improve quality of life, and could have led to macrolide resistance. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Omalizumab management beyond clinical trials: The added value of a network model
Conclusion Our retrospective analysis represents a preliminary report from the NEONet activity. It confirmed omalizumab efficacy and provided some new insights about its impact on lung function and on comorbid rhinitis. The network approach, under a prospective view, allows creating a large uniform database, by means of a standardized shared tool for data collecting, and joining a multidisciplinary expertise. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler
Conclusions SFC 50/250 μg Rotacaps/Rotahaler (L) showed comparable systemic exposure to Diskus in terms of FP AUC and SALM AUC and C max. These results merit further progression of SFC 50/250 μg Rotacaps/Rotahaler (L) to phase 3 clinical evaluation in asthma and COPD patients. The lack of pharmacokinetic comparability between the inhalers for SFC 50/100 μg requires further evaluation. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Partial versus maximal forced exhalations in COPD: Enhanced signal detection for novel therapies
Conclusions The use of PF800 increased detection of a BDR in COPD compared to FEV1 alone and may reflect small airway responses. The PEFV maneuver is simple, repeatable and may avoid some of the theoretical disadvantages of FEV1. The role of PF800 for evaluating novel anti-inflammatory agents remains to be determined. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects
Conclusion There was no clinically significant effect on QTcF observed following 10-days' treatment with inhaled UMEC/VI 125/25 μg or UMEC 500 μg compared with placebo. The supratherapeutic dose of UMEC/VI 500/100 μg prolonged QTcF by 6.4 ms (90% CI: 4.3, 8.5) at 10 min and 8.2 ms (90% CI: 6.2, 10.2) at 30 min compared with placebo, following which QTcF interval difference from placebo declined rapidly.. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): Nicolas Lindegger , Patricia N. Sidharta , Kathrin Reseski , Jasper Dingemanse Macitentan is an orally active dual endothelin receptor antagonist, which demonstrated a reduction of the risk of morbidity/mortality events in pulmonary arterial hypertension patients. This double-blind, randomized, placebo- and positive-controlled, four-way crossover thorough QTc study was designed to investigate the effects of therapeutic and supratherapeutic doses of macitentan on cardiac repolarization in healthy male and fem...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Airway and systemic oxidant-antioxidant dysregulation in asthma: A possible scenario of oxidants spill over from lung into blood
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): A. Nadeem , N. Siddiqui , Naif O. Alharbi , Mohamed M. Alharbi Asthma is characterized by repeated episodes of airway obstruction and an ongoing cycle of airway inflammation. Reactive oxygen species (ROS) produced by inflammatory cells in the lung play a key role in the pathogenesis as well as amplification of inflammation in asthmatic airways. Several enzymatic and non-enzymatic antioxidants are available in the lung and systemic circulation to counteract ROS-mediated damage on various biomolecules such as ...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury
Conclusions Atrial natriuretic peptide had a protective effect in the lipopolysaccharide-induced acute lung injury model. Atrial natriuretic peptide may be of value in therapeutic strategies aimed at the treatment of acute lung injury such as pneumonia or acute respiratory distress syndrome. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma
In conclusion, JNJ-40929837 demonstrated target engagement in blood and sputum. No significant impact in response to allergen inhalation was observed with JNJ-40929837 versus placebo. Registration This study is registered at ClinicalTrials.gov: NCT01241422. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): David G.S. Farmer , Marie-Ann Ewart , Kirsty M. Mair , Simon Kennedy The calgranulin-like protein MTS1/S100A4 and the receptor for advanced glycation end-products (RAGE) have recently been implicated in mediating pulmonary arterial smooth muscle cell proliferation and vascular remodelling in experimental pulmonary arterial hypertension (PH). Here, the effects of RAGE antagonism upon 2 weeks of hypobaric hypoxia (10% O2)-induced PH in mice were assessed. Treatment with sRAGE was protective against hypobaric h...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Role of the nitric oxide–soluble guanylyl cyclase pathway in obstructive airway diseases
Publication date: October 2014 Source:Pulmonary Pharmacology & Therapeutics, Volume 29, Issue 1 Author(s): Lisa L. Dupont , Constantinos Glynos , Ken R. Bracke , Peter Brouckaert , Guy G. Brusselle Nitric oxide (NO) is a gaseotransmitter, which is involved in many signaling processes in health and disease. Three enzymes generate NO from l-arginine, with citrulline formed as a by-product: neuronal NO synthase (nNOS or NOS1), endothelial NOS (eNOS or NOS3) and inducible NOS (iNOS or NOS2). NO is a ligand of soluble guanylyl cyclase (sGC), an intracellular heterodimer enzyme that catalyzes the conversion of guanosin...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD
Conclusions Inhaled budesonide and systemic methylprednisolone have the same effects on systemic inflammation of AECOPD. Inhaled corticosteroid alone could instead systemic corticosteroid in AECOPD treatment. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Luteolin inhibited the gene expression, production and secretion of MUC5AC mucin via regulation of nuclear factor kappa B signaling pathway in human airway epithelial cells
In this study, we investigated whether luteolin significantly affects the secretion, production and gene expression of airway mucin. Confluent NCI-H292 cells were pretreated with luteolin for 30 min and then stimulated with EGF (epidermal growth factor) or PMA (phorbol 12-myristate 13-acetate) for 24 h or the indicated periods. The MUC5AC mucin gene expression was measured by RT-PCR. Production and secretion of MUC5AC mucin protein were measured by ELISA. To elucidate the action mechanism of luteolin, effect of luteolin on PMA-induced NF-κB signaling pathway was investigated by western blot analysis. The re...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Hypoxia increases pulmonary arterial thromboxane receptor internalization independent of receptor sensitization
Publication date: Available online 12 October 2014 Source:Pulmonary Pharmacology & Therapeutics Author(s): J. Fediuk , A.S. Sikarwar , P.P. Lizotte , M. Hinton , N. Nolette , S. Dakshinamurti Persistent Pulmonary Hypertension of the Newborn (PPHN) is characterized by sustained vasospasm and an increased thromboxane:prostacyclin ratio. Thromboxane (TP) receptors signal via Gαq to mobilize IP3 and Ca2+, causing pulmonary arterial constriction. We have previously reported increased TP internalization in hypoxic pulmonary arterial (PA) myocytes. Serum-deprived PA myocytes were grown in normoxia (NM) or hypoxia ...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Pulmonary vascular changes in asthma and COPD
Publication date: Available online 12 October 2014 Source:Pulmonary Pharmacology & Therapeutics Author(s): Louise M. Harkness , Varsha Kanabar , Hari S. Sharma , Gunilla Westergren-Thorsson , Anna-Karin Larsson-Callerfelt In chronic lung disorders such as in asthma and chronic obstructive pulmonary disease (COPD) there is increased bronchial angiogenesis and remodelling of pulmonary vessels culminating to altered bronchial and pulmonary circulation. The involvement of residential cells such as endothelial cells, smooth muscle cells and pulmonary fibroblasts, all appear to have a crucial role in the progression of...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease
Conclusions Indacaterol and tiotropium combination therapy improved airflow limitation and respiratory resistances. Adding indacaterol to tiotropium, or tiotropium to indacaterol, had similar effects on airflow limitation. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Roflumilast added to triple therapy in patients with severe COPD: A real life study
Conclusions Roflumilast, when added to triple therapy, reduces exacerbations in a “real-life” population of severe COPD patients with frequent exacerbations. However, side effects are more common and lead more frequently to discontinuation of therapy than has been reported in trials. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research

Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation
Publication date: Available online 4 November 2014 Source:Pulmonary Pharmacology & Therapeutics Author(s): Elena Rodriguez , Lauren Sakowski , Grace M. Hobson , Milena Hirata Armani , Portia A. Kreiger , Yan Zhu , Scott A. Waldman , Thomas H. Shaffer Mice with Plp1gene duplication model the most common form of Pelizaeus-Merzbacher disease (PMD), a CNS disease in which patients may suffer respiratory complications. We hypothesized that affected mice would lack airway responsiveness compared to wild-type and carrier mice during methacholine challenge. Wild-type (n=10), carrier female (n=6) and affected male (n=8) m...
Source: Pulmonary Pharmacology and Therapeutics - November 6, 2014 Category: Respiratory Medicine Source Type: research